Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
CHILDHOOD EPILEPSY - CURRENT THERAPEUTIC RECOMMENDATIONS
Autore:
GILMAN JT; DUCHOWNY M;
Indirizzi:
MIAMI CHILDRENS HOSP,DIV CLIN PHARMACOL,CLIN PHARMACOL & PHARMACOKINET LAB,6125 SW 31ST ST MIAMI FL 33155 MIAMI CHILDRENS HOSP,DEPT NEUROSCI MIAMI FL 00000 MIAMI CHILDRENS HOSP,CTR COMPREHENS EPILEPSY MIAMI FL 00000 MIAMI CHILDRENS HOSP,PHARMACOKINET LAB MIAMI FL 00000
Titolo Testata:
CNS DRUGS
fascicolo: 3, volume: 1, anno: 1994,
pagine: 180 - 192
SICI:
1172-7047(1994)1:3<180:CE-CTR>2.0.ZU;2-X
Fonte:
ISI
Lingua:
ENG
Soggetto:
JUVENILE MYOCLONIC EPILEPSY; 1ST UNPROVOKED SEIZURE; TONIC CLONIC SEIZURES; TERM FOLLOW-UP; INFANTILE SPASMS; ANTIEPILEPTIC DRUGS; FEBRILE SEIZURES; VALPROIC ACID; REFRACTORY EPILEPSY; CHILDREN;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
94
Recensione:
Indirizzi per estratti:
Citazione:
J.T. Gilman e M. Duchowny, "CHILDHOOD EPILEPSY - CURRENT THERAPEUTIC RECOMMENDATIONS", CNS DRUGS, 1(3), 1994, pp. 180-192

Abstract

The pharmacotherapy of epilepsy in children must account for a numberof specific issues. The nature of epileptic disorders found in children differs from that in adults. For example, epilepsies of childhood are more likely to be developmentally or genetically based than those found in adults. Children also differ from adults in indications for antiepileptic drugs. Indeed, some types of childhood epilepsy do not require specific pharmacological treatment since prognosis is often excellent without therapy. This is especially true for children who are neurologically normal and those with benign epilepsy syndromes that have a characteristic electroclinical presentation, such as febrile seizures. In contrast, children with evidence of brain damage or those with serious epilepsy syndromes must be treated promptly. Once it has been decided that treatment is necessary, the choice of treatment should be based on a comparison of efficacy and tolerability of individual antiepileptic agents. The spectrum of toxicity is often different in younger patients from that in adults, and adverse effects that are acceptable in adults may be cause for discontinuation of therapy in children. Intellectual, cognitive and behavioural toxicity are particularly unacceptable. Establishing sustained therapeutic serum concentrations in children also requires specific attention. Rapid gastrointestinal transit times and interactions with milk and infant formulas may pose special management problems. Toxic metabolites of antiepileptic drugs are frequently produced in children. This can lead to drug hypersensitivity and other possible conditions, such as valproic acid (sodium valproate)-induced hepatotoxicity. Unless specific paediatric data are obtained, recommendations for the treatment of epilepsies in children will continue to be based on studies in adults and on anecdotal observations. Given the high prevalence and significant morbidity of childhood epilepsies, further studies of treatments are urgently needed.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/11/20 alle ore 09:59:33